Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 38

1.

Oncogenic Gene Fusion Detection Using Anchored Multiplex Polymerase Chain Reaction Followed by Next Generation Sequencing.

Seager M, Aisner DL, Davies KD.

J Vis Exp. 2019 Jul 5;(149). doi: 10.3791/59895.

PMID:
31329176
2.

Wake Up and Smell the Fusions: Single-Modality Molecular Testing Misses Drivers.

Davies KD, Aisner DL.

Clin Cancer Res. 2019 Aug 1;25(15):4586-4588. doi: 10.1158/1078-0432.CCR-19-1361. Epub 2019 Jun 3.

PMID:
31160470
3.

Ready or Not, Here I Come: Inflammatory Myofibroblastic Tumors With Kinase Alterations Revealed Through Molecular Hide and Seek.

Davies KD, Villalobos VM, Aisner DL.

J Thorac Oncol. 2019 May;14(5):758-760. doi: 10.1016/j.jtho.2019.02.006. No abstract available.

PMID:
31027738
4.

Molecular markers in recurrent stage I, grade 1 endometrioid endometrial cancers.

Moroney MR, Davies KD, Wilberger AC, Sheeder J, Post MD, Berning AA, Fisher C, Lefkowits C, Guntupalli SR, Behbakht K, Corr BR.

Gynecol Oncol. 2019 Jun;153(3):517-520. doi: 10.1016/j.ygyno.2019.03.100. Epub 2019 Mar 22.

PMID:
30910249
5.

MET Copy Number as a Secondary Driver of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Resistance in EGFR-Mutant Non-Small-Cell Lung Cancer.

Camidge DR, Davies KD.

J Clin Oncol. 2019 Apr 10;37(11):855-857. doi: 10.1200/JCO.19.00033. Epub 2019 Feb 27. No abstract available.

PMID:
30811294
6.

Persistent Dysphagia Rate After Antireflux Surgery is Similar for Nissen Fundoplication and Partial Fundoplication.

Walle KV, Funk LM, Xu Y, Davies KD, Greenberg J, Shada A, Lidor A.

J Surg Res. 2019 Mar;235:52-57. doi: 10.1016/j.jss.2018.09.036. Epub 2018 Oct 23.

PMID:
30691837
7.

DNA-Based versus RNA-Based Detection of MET Exon 14 Skipping Events in Lung Cancer.

Davies KD, Lomboy A, Lawrence CA, Yourshaw M, Bocsi GT, Camidge DR, Aisner DL.

J Thorac Oncol. 2019 Apr;14(4):737-741. doi: 10.1016/j.jtho.2018.12.020. Epub 2019 Jan 9.

PMID:
30639620
8.

Latina/o Children Living With an Immigrant Mother With Depression: Developmental and Cultural Nuances in Recognition and Coping.

Valdez CR, Raines CR, Davies KD, D'Costa S.

Fam Process. 2018 Oct 27. doi: 10.1111/famp.12398. [Epub ahead of print]

PMID:
30368803
9.

MERTK Mediates Intrinsic and Adaptive Resistance to AXL-targeting Agents.

McDaniel NK, Cummings CT, Iida M, Hülse J, Pearson HE, Vasileiadi E, Parker RE, Orbuch RA, Ondracek OJ, Welke NB, Kang GH, Davies KD, Wang X, Frye SV, Earp HS, Harari PM, Kimple RJ, DeRyckere D, Graham DK, Wheeler DL.

Mol Cancer Ther. 2018 Nov;17(11):2297-2308. doi: 10.1158/1535-7163.MCT-17-1239. Epub 2018 Aug 9.

PMID:
30093568
10.

Final Report of a Phase I Trial of Olaparib with Cetuximab and Radiation for Heavy Smoker Patients with Locally Advanced Head and Neck Cancer.

Karam SD, Reddy K, Blatchford PJ, Waxweiler T, DeLouize AM, Oweida A, Somerset H, Marshall C, Young C, Davies KD, Kane M, Tan AC, Wang XJ, Jimeno A, Aisner DL, Bowles DW, Raben D.

Clin Cancer Res. 2018 Oct 15;24(20):4949-4959. doi: 10.1158/1078-0432.CCR-18-0467. Epub 2018 Jul 3.

PMID:
30084837
11.

Comparison of Molecular Testing Modalities for Detection of ROS1 Rearrangements in a Cohort of Positive Patient Samples.

Davies KD, Le AT, Sheren J, Nijmeh H, Gowan K, Jones KL, Varella-Garcia M, Aisner DL, Doebele RC.

J Thorac Oncol. 2018 Oct;13(10):1474-1482. doi: 10.1016/j.jtho.2018.05.041. Epub 2018 Jun 20.

PMID:
29935306
12.

Resistance Mechanisms to Targeted Therapies in ROS1+ and ALK+ Non-small Cell Lung Cancer.

McCoach CE, Le AT, Gowan K, Jones K, Schubert L, Doak A, Estrada-Bernal A, Davies KD, Merrick DT, Bunn PA Jr, Purcell WT, Dziadziuszko R, Varella-Garcia M, Aisner DL, Camidge DR, Doebele RC.

Clin Cancer Res. 2018 Jul 15;24(14):3334-3347. doi: 10.1158/1078-0432.CCR-17-2452. Epub 2018 Apr 10.

13.

Clinical Utility of Cell-Free DNA for the Detection of ALK Fusions and Genomic Mechanisms of ALK Inhibitor Resistance in Non-Small Cell Lung Cancer.

McCoach CE, Blakely CM, Banks KC, Levy B, Chue BM, Raymond VM, Le AT, Lee CE, Diaz J, Waqar SN, Purcell WT, Aisner DL, Davies KD, Lanman RB, Shaw AT, Doebele RC.

Clin Cancer Res. 2018 Jun 15;24(12):2758-2770. doi: 10.1158/1078-0432.CCR-17-2588. Epub 2018 Mar 29.

14.

Validation of a Targeted RNA Sequencing Assay for Kinase Fusion Detection in Solid Tumors.

Reeser JW, Martin D, Miya J, Kautto EA, Lyon E, Zhu E, Wing MR, Smith A, Reeder M, Samorodnitsky E, Parks H, Naik KR, Gozgit J, Nowacki N, Davies KD, Varella-Garcia M, Yu L, Freud AG, Coleman J, Aisner DL, Roychowdhury S.

J Mol Diagn. 2017 Sep;19(5):682-696. doi: 10.1016/j.jmoldx.2017.05.006. Epub 2017 Aug 9.

15.

EGFR Mediates Responses to Small-Molecule Drugs Targeting Oncogenic Fusion Kinases.

Vaishnavi A, Schubert L, Rix U, Marek LA, Le AT, Keysar SB, Glogowska MJ, Smith MA, Kako S, Sumi NJ, Davies KD, Ware KE, Varella-Garcia M, Haura EB, Jimeno A, Heasley LE, Aisner DL, Doebele RC.

Cancer Res. 2017 Jul 1;77(13):3551-3563. doi: 10.1158/0008-5472.CAN-17-0109. Epub 2017 Apr 20.

16.

Autophagy inhibition overcomes multiple mechanisms of resistance to BRAF inhibition in brain tumors.

Mulcahy Levy JM, Zahedi S, Griesinger AM, Morin A, Davies KD, Aisner DL, Kleinschmidt-DeMasters BK, Fitzwalter BE, Goodall ML, Thorburn J, Amani V, Donson AM, Birks DK, Mirsky DM, Hankinson TC, Handler MH, Green AL, Vibhakar R, Foreman NK, Thorburn A.

Elife. 2017 Jan 17;6. pii: e19671. doi: 10.7554/eLife.19671.

17.

Dramatic Response to Crizotinib in a Patient with Lung Cancer Positive for an HLA-DRB1-MET Gene Fusion.

Davies KD, Ng TL, Estrada-Bernal A, Le AT, Ennever PR, Camidge DR, Doebele RC, Aisner DL.

JCO Precis Oncol. 2017;2017(1). doi: 10.1200/PO.17.00117. Epub 2017 Aug 29. No abstract available.

18.

Desmoplastic infantile astrocytoma/ganglioglioma with rare BRAF V600D mutation.

Greer A, Foreman NK, Donson A, Davies KD, Kleinschmidt-DeMasters BK.

Pediatr Blood Cancer. 2017 Jun;64(6). doi: 10.1002/pbc.26350. Epub 2016 Nov 10.

19.

Multi-Institutional FASTQ File Exchange as a Means of Proficiency Testing for Next-Generation Sequencing Bioinformatics and Variant Interpretation.

Davies KD, Farooqi MS, Gruidl M, Hill CE, Woolworth-Hirschhorn J, Jones H, Jones KL, Magliocco A, Mitui M, O'Neill PH, O'Rourke R, Patel NM, Qin D, Ramos E, Rossi MR, Schneider TM, Smith GH, Zhang L, Park JY, Aisner DL.

J Mol Diagn. 2016 Jul;18(4):572-9. doi: 10.1016/j.jmoldx.2016.03.002. Epub 2016 May 4.

PMID:
27155050
20.

Tumor-Infiltrating T Cells and the PD-1 Checkpoint Pathway in Advanced Differentiated and Anaplastic Thyroid Cancer.

Bastman JJ, Serracino HS, Zhu Y, Koenig MR, Mateescu V, Sams SB, Davies KD, Raeburn CD, McIntyre RC Jr, Haugen BR, French JD.

J Clin Endocrinol Metab. 2016 Jul;101(7):2863-73. doi: 10.1210/jc.2015-4227. Epub 2016 Apr 5.

21.

Rearranging Detection of Gene Rearrangements.

Davies KD, Doebele RC, Aisner DL.

J Thorac Oncol. 2015 Aug;10(8):1129-30. doi: 10.1097/JTO.0000000000000603. No abstract available.

22.

Small Molecule Inhibition of MERTK Is Efficacious in Non-Small Cell Lung Cancer Models Independent of Driver Oncogene Status.

Cummings CT, Zhang W, Davies KD, Kirkpatrick GD, Zhang D, DeRyckere D, Wang X, Frye SV, Earp HS, Graham DK.

Mol Cancer Ther. 2015 Sep;14(9):2014-22. doi: 10.1158/1535-7163.MCT-15-0116. Epub 2015 Jul 10.

23.

The TAM family: phosphatidylserine sensing receptor tyrosine kinases gone awry in cancer.

Graham DK, DeRyckere D, Davies KD, Earp HS.

Nat Rev Cancer. 2014 Dec;14(12):769-85. doi: 10.1038/nrc3847. Review.

PMID:
25568918
24.

Mer590, a novel monoclonal antibody targeting MER receptor tyrosine kinase, decreases colony formation and increases chemosensitivity in non-small cell lung cancer.

Cummings CT, Linger RM, Cohen RA, Sather S, Kirkpatrick GD, Davies KD, DeRyckere D, Earp HS, Graham DK.

Oncotarget. 2014 Nov 15;5(21):10434-45.

25.

Resistance to ROS1 inhibition mediated by EGFR pathway activation in non-small cell lung cancer.

Davies KD, Mahale S, Astling DP, Aisner DL, Le AT, Hinz TK, Vaishnavi A, Bunn PA Jr, Heasley LE, Tan AC, Camidge DR, Varella-Garcia M, Doebele RC.

PLoS One. 2013 Dec 13;8(12):e82236. doi: 10.1371/journal.pone.0082236. eCollection 2013.

26.

Oncogenic and drug-sensitive NTRK1 rearrangements in lung cancer.

Vaishnavi A, Capelletti M, Le AT, Kako S, Butaney M, Ercan D, Mahale S, Davies KD, Aisner DL, Pilling AB, Berge EM, Kim J, Sasaki H, Park S, Kryukov G, Garraway LA, Hammerman PS, Haas J, Andrews SW, Lipson D, Stephens PJ, Miller VA, Varella-Garcia M, Jänne PA, Doebele RC.

Nat Med. 2013 Nov;19(11):1469-1472. doi: 10.1038/nm.3352. Epub 2013 Oct 27.

27.

Molecular pathways: ROS1 fusion proteins in cancer.

Davies KD, Doebele RC.

Clin Cancer Res. 2013 Aug 1;19(15):4040-5. doi: 10.1158/1078-0432.CCR-12-2851. Epub 2013 May 29. Review.

28.

Identifying and targeting ROS1 gene fusions in non-small cell lung cancer.

Davies KD, Le AT, Theodoro MF, Skokan MC, Aisner DL, Berge EM, Terracciano LM, Cappuzzo F, Incarbone M, Roncalli M, Alloisio M, Santoro A, Camidge DR, Varella-Garcia M, Doebele RC.

Clin Cancer Res. 2012 Sep 1;18(17):4570-9. doi: 10.1158/1078-0432.CCR-12-0550. Epub 2012 Aug 23.

29.

Radiation induces acute alterations in neuronal function.

Wu PH, Coultrap S, Pinnix C, Davies KD, Tailor R, Ang KK, Browning MD, Grosshans DR.

PLoS One. 2012;7(5):e37677. doi: 10.1371/journal.pone.0037677. Epub 2012 May 25.

30.

Single-agent inhibition of Chk1 is antiproliferative in human cancer cell lines in vitro and inhibits tumor xenograft growth in vivo.

Davies KD, Humphries MJ, Sullivan FX, von Carlowitz I, Le Huerou Y, Mohr PJ, Wang B, Blake JF, Lyon MA, Gunawardana I, Chicarelli M, Wallace E, Gross S.

Oncol Res. 2011;19(7):349-63.

PMID:
21936404
31.

Chk1 inhibition and Wee1 inhibition combine synergistically to impede cellular proliferation.

Davies KD, Cable PL, Garrus JE, Sullivan FX, von Carlowitz I, Huerou YL, Wallace E, Woessner RD, Gross S.

Cancer Biol Ther. 2011 Nov 1;12(9):788-96. doi: 10.4161/cbt.12.9.17673. Epub 2011 Nov 1.

PMID:
21892012
32.

Oxidative stress status accompanying diabetic bladder cystopathy results in the activation of protein degradation pathways.

Kanika ND, Chang J, Tong Y, Tiplitsky S, Lin J, Yohannes E, Tar M, Chance M, Christ GJ, Melman A, Davies KD.

BJU Int. 2011 May;107(10):1676-84. doi: 10.1111/j.1464-410X.2010.09655.x. Epub 2010 Sep 21.

33.

A widespread, itchy papular eruption.

Davies KD, Davies JH.

Clin Exp Dermatol. 2010 Dec;35(8):937-9. doi: 10.1111/j.1365-2230.2010.03837.x. No abstract available.

PMID:
21054490
34.

An alternative treatment option for compensatory hyperhidrosis after endoscopic thoracic sympathectomy.

Davies KD, Lawton N.

Clin Exp Dermatol. 2010 Jan;35(1):105-6. doi: 10.1111/j.1365-2230.2009.03371.x. No abstract available.

PMID:
20028410
35.

Phospho-regulation of synaptic and extrasynaptic N-methyl-d-aspartate receptors in adult hippocampal slices.

Goebel-Goody SM, Davies KD, Alvestad Linger RM, Freund RK, Browning MD.

Neuroscience. 2009 Feb 18;158(4):1446-59. doi: 10.1016/j.neuroscience.2008.11.006. Epub 2008 Nov 8.

PMID:
19041929
36.

Long term synaptic depression that is associated with GluR1 dephosphorylation but not alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor internalization.

Davies KD, Goebel-Goody SM, Coultrap SJ, Browning MD.

J Biol Chem. 2008 Nov 28;283(48):33138-46. doi: 10.1074/jbc.M803431200. Epub 2008 Sep 26.

37.

Dual mechanism of a natural CaMKII inhibitor.

Vest RS, Davies KD, O'Leary H, Port JD, Bayer KU.

Mol Biol Cell. 2007 Dec;18(12):5024-33. Epub 2007 Oct 17.

38.

alphaCaMKII autophosphorylation levels differ depending on subcellular localization.

Davies KD, Alvestad RM, Coultrap SJ, Browning MD.

Brain Res. 2007 Jul 16;1158:39-49. Epub 2007 May 10.

Supplemental Content

Loading ...
Support Center